Compare Caterpillar Inc (CAT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caterpillar Inc vs Incyte Corporation — how do they compare? Caterpillar Inc trades at $927.13 (market cap $429.89B), while Incyte Corporation trades at $112.82 (market cap $22.95B). The key difference: Caterpillar Inc is far larger — about 18.7× Incyte Corporation's market cap, and Caterpillar Inc pays a 0.7% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CAT | INCY | |
|---|---|---|
Market Cap | $429.89B | $22.95B |
Sector | Industrials | Health |
52-Week High | $1.06K | $118.52 |
52-Week Low | $404.64 | $67.38 |
Enterprise Value | $468.88B | $18.97B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $931.47, down 2.2% on the day, but has gained 51% year-to-date, driven by strong earnings beats and AI-related infrastructure demand. The stock shows a bullish moving average signal but neutral overall technicals, with support near $922. Revenue reached $67.59 billion in 2025, with a net income margin of 13.33%, though valuation multiples like a P/E of 46.48 appear elevated. Recent news highlights its role in the AI data center boom, with the Power & Energy segment seeing significant backlog growth.
The outlook remains positive given analyst consensus and AI-driven tailwinds, but high valuation and exposure to economic cycles pose risks. With 55% of analysts rating it a Buy and a consensus price target of $1,030, upside potential exists, though investors should weigh margin pressures and debt levels against growth catalysts from data center and infrastructure spending.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caterpillar Inc
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
